Shares of Novo Nordisk have settled into a stretch of pronounced weakness, leaving holders to weigh whether the recent consolidation offers an entry point or whether operational strain will drag the valuation even lower. The stock closed yesterday at EUR 34.12 and has shed 22 percent since the start of the year.
That decline captures a shift in how the market views the Danish drugmaker. For years, the company rode an exceptional boom in GLP-1 therapies; now the durability of that growth is back under the microscope. Investors want hard evidence that Novo can defend its position against a strengthening field of rivals.
Ozempic’s US Trajectory Takes Center Stage
The US business for blockbuster Ozempic sits at the heart of the debate, since it will determine how resilient market share proves to be under mounting competitive pressure. On Monday, BMO Capital flagged that US market share is on the decline, cutting its price target on the stock from $47 to $40 while keeping a Market Perform rating.
A statistical quirk adds further noise to the picture. Last year, rebate advantages in billing — so-called gross-to-net benefits — flattered results. Those prior-year effects are likely to make an apparent drop in US Ozempic revenue in the third quarter of 2026 look sharper than it really is, distorting the underlying demand trend. BMO’s analysts, however, did not point to this comparison base as the sole driver of the share price losses.
A Buyback Running at Full Tilt
Support for the stock is coming from the company’s own capital allocation. A little over a week ago, Novo Nordisk reported substantial progress on a buyback program worth up to DKK 15 billion. Since early February, it has repurchased shares for more than DKK 10 billion — DKK 10,558,876,422 to be precise — lifting its holding of own B shares to 1.2 percent of share capital. By the October 9 cut-off date, 37,849,179 B shares had been bought back.
Management’s steady purchases telegraph confidence in the group’s substance, and market participants read the move as an effort to shore up shareholder faith during a volatile stretch.
FDA Extends Denecimig Review
Mid-term prospects are also taking shape in the pipeline. Roughly two weeks ago, Novo Nordisk disclosed that the US Food and Drug Administration has extended its review of Denecimig for the treatment of hemophilia A. The delay stems from ongoing remediation work at a manufacturing site.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Because the agency raised no concerns about clinical efficacy or safety data, the company still aims for a US market launch in the first half of 2027, subject to regulatory approval. Novo stressed that the holdup does not affect its financial guidance for the current fiscal year.
Fresh Data on Semaglutide
Beyond market and regulatory matters, the company has released new results from clinical research. In an analysis presented at EASD, 23 of 26 participants with obesity and elevated liver fat returned to normal liver fat levels after 72 weeks of treatment with semaglutide. The findings demonstrate the therapeutic potential of the active ingredient beyond pure weight reduction.
Risks That Could Extend the Downtrend
Set against these positives are tangible risks that could trigger a continuation of the downward trend. Should the US market share decline prove to be a structural trend rather than a prior-year accounting effect, a lasting margin erosion looms. Growing pressure on reimbursement prices in the US healthcare system could put a noticeable brake on growth momentum.
Market skepticism is already showing up in more cautious valuations. Delays in fixing manufacturing deficiencies always carry the risk of further postponements, even though regulators left the clinical data unobjected.
The Quarterly Report Is the Next Fork in the Road
What happens next hinges on the interplay between chart levels and operational delivery. As long as support around the 52-week low of EUR 30.25 holds, the chance of a valuation stabilization stays alive; if US revenue momentum deteriorates more sharply than feared in the third quarter of 2026, selling pressure is likely to build again.
The decisive catalyst for market participants is the upcoming release of the third-quarter 2026 financial report. That date will reveal the extent to which Ozempic’s market share losses genuinely trace back to base effects. Until those figures land, investors should brace for a period of heightened volatility.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from October 15 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 15.
Novo Nordisk: Buy or sell? Read more here...
